Sources: MHRA Drug Safety Update: Topiramate Pregnancy Prevention Programme and risks (20232024)
It also points to the need for better strategies to make these treatments more accessible and available to those who need them. Prior to this research, a small study of 106 postmenopausal women published in 2024 in the medical journal Menopause found that those who were on both MHT and the GLP-1 drug semaglutide had lost about 16 percent of their total body weight after a year, compared to 12 percent for women on a GLP-1 alone
Established cardiovascular disease or high cardiovascular risk
Extraction, characterization and functional properties of soluble proteins from edible grasshopper ( Schistocerca gregaria ) and honey bee ( Apis mellifera )
Thus, epg-5 , tbx-2 and C17H12.36 are indirect or secondary targets of GLP-1 signaling, with their RNA accumulation dependent on the downstream lst-1 and sygl-1 gene activity
The EU agency estimated that this condition may affect 1 in 10,000 people taking semaglutides for at least one year